Alopexx Oncology LLC, of Concord, Mass., disclosed data from a phase I trial of DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 (IL-2) and a CD20-targeting monoclonal antibody. Read More
Abbvie Inc., of North Chicago, said the European Commission has granted conditional marketing authorization for Venclyxto (venetoclax) monotherapy for the treatment of chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. The drug is being developed by Abbvie and Genentech, of South San Francisco, a member of the Roche Group. Read More
Ohr Pharmaceutical Inc., of New York, priced a registered public offering of an aggregate of 3.87 million shares of common stock at $2 per share. Read More
HONG KONG – In yet another of a growing list of acquisitions, Chinese drugmaker Luye Pharma Group Ltd. (2186.HK) has inked an agreement to acquire Swiss-based Acino Holdings’ transdermal drug delivery systems (TDS) business. Read More
The hearing at the U.S. Patent and Trademark Office regarding two patents for clustered, regularly-interspaced short palindromic repeats (CRISPR) is a pivotal moment for the intellectual properties associated with the technology, but Bob Underwood, a partner at the Chicago office of McDermott Will & Emery, told BioWorld Today that prognostication on the outcome is a dicey exercise. Read More
HONG KONG – Eutilex Co. Ltd. has raised $18 million in a series A financing, the largest private funding round for a startup in South Korea’s life sciences sector. Read More
Voyager Therapeutics Inc. has a Parkinson’s disease gene therapy that could last “essentially for as long as the patient lives, but at least 15 or 20 years,” CEO Steven Paul told BioWorld Today, commenting on phase Ib results with VY-AADC01. Read More
SHANGHAI – Bioatla LLC, of San Diego, has received $36 million from Chinese conglomerate Beijing Sinobioway Group Co. Ltd. in a co-development partnership that has netted the American partner $100 million in program payments and equity investments. Read More
TCR2 Therapeutics Inc., a Cambridge, Mass.-based immunotherapy developer targeting solid tumors with an approach to T-cell therapies that its execs say will improve safety and durability, has landed a $44.5 million series A financing expected to carry its anticancer aspirations into the clinic by the end of 2018. Read More
Radius Health Inc., of Waltham, Mass., reported data from two ongoing phase I studies of RAD1901, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. As of Oct. 7, 2016, 20 patients were treated in the RAD1901 phase Ib safety expansion cohort at the 400 mg dose. Read More
